首页|siRNA转染试剂的全面对比研究

siRNA转染试剂的全面对比研究

扫码查看
siRNA已经成为生物研究的常用工具,也是目前最具潜力的下一代基因治疗药物.将siRNA成功转染进入细胞,仍然是限制siRNA广泛应用的关键技术,对于难转染细胞尤其如此.siRNA转染效率是摄取、细胞利用率及细胞毒性的综合作用结果,更高的转染效率通常需要高摄取、高细胞利用率和低细胞毒性.本研究旨在比较不同的转染试剂递送siRNA的摄取、siRNA敲低效率和毒性情况.新开发的CALNP RNAi转染试剂与传统转染试剂的摄取行为不同,转染效率显著高于传统转染试剂,同时毒性最低.CALNP RNAi转染试剂为难转染细胞的RNA干扰带来了新的选择.
A comprehensive comparative analysis of transfection reagents for siRNA delivery
siRNAs have emerged as essential tools in biological research and hold promise as next-generation therapeutics for gene therapy.However,achieving successful and safe siRNA transfection remains a challenge,especially for cells that are notoriously difficult to transfect.The efficiency of siRNA transfection is influenced by factors such as uptake,cellular availability,and cytotoxicity.Generally,higher transfection efficiency is associated with increased uptake,improved cellular availability,and reduced cytotoxicity.This study aimed to compare the performance of different transfection reagents in delivering siRNAs,focusing on their uptake,knockdown efficacy,and toxicity.All reagents measured in here were good uptaken in HepG2 and HEK293T cells,but low uptake in RAW264.7 cells.Among them,the newly developed CALNP RNAi transfection reagent exhibited distinct uptake profiles when compared to other transfection reagents across various tested cell lines.CALNP RNAi consistently demonstrated superior transfection efficiency and minimal cell toxicity in all the tested cell lines.Furthermore,CALNP RNAi held promise for enabling RNA interference in"hard-to-transfect"cells.This research contributed to our understanding of effective siRNA delivery methods and highlighted the potential of CALNP RNAi transfection reagent as a valuable tool for gene silencing,especially in challenging cellular contexts.

Transfection reagentsiRNARNA interfering"Hard-to-transfect"cells

佟淑文、齐宪荣

展开 >

北京大学药学院药剂学系,北京 100191

北京大学前沿交叉学科研究院,北京 100871

北京多纳医药科技有限公司,北京 102206

北京大学药学院分子药剂学与新释药系统北京市重点实验室,北京 100191

展开 >

转染试剂 siRNA RNA干扰 难转染细胞

"Open Competition to Select the Best Candidates"Key Technology Program for Nucleic Acid Drugs of NCTIB北京市自然科学基金

NCTIB2022HS01001L202044

2024

中国药学(英文版)
中国药学会

中国药学(英文版)

CSTPCD
影响因子:0.534
ISSN:1003-1057
年,卷(期):2024.33(1)
  • 22